By continuing, you agree to the Terms of Service.
This website uses cookies to enhance your browsing experience. Learn More.
Essential Cookies
Optional Cookies
Login

Climb Bio, Inc. (CLYM)

NASDAQ Currency in USD
$2.40
+$0.02
+0.84%
Last Update: 11 Sept 2025, 20:00
$162.63M
Market Cap
0.00
P/E Ratio (TTM)
Forward Dividend Yield
$1.05 - $8.79
52 Week Range

CLYM Stock Price Chart

Explore Climb Bio, Inc. interactive price chart. Choose custom timeframes to analyze CLYM price movements and trends.

CLYM Company Profile

Discover essential business fundamentals and corporate details for Climb Bio, Inc. (CLYM) to support your stock research and investment decisions.

Sector

Healthcare

Industry

Biotechnology

IPO Date

Employees

17.00

CEO

Aoife M. Brennan BAO, BCh, MB, MMSc

Description

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

CLYM Financial Timeline

Browse a chronological timeline of Climb Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.

Upcoming earnings on 11 Nov 2025

EPS estimate is -$0.17.

Earnings released on 12 Aug 2025

EPS came in at -$0.13 surpassing the estimated -$0.19 by +31.58%.

Earnings released on 14 May 2025

EPS came in at -$0.31 falling short of the estimated -$0.15 by -106.67%.

Earnings released on 25 Mar 2025

EPS came in at -$0.13 surpassing the estimated -$0.15 by +13.33%.

Earnings released on 12 Nov 2024

EPS came in at -$0.13 .

Earnings released on 14 Aug 2024

EPS came in at -$1.81 .

Earnings released on 15 May 2024

EPS came in at -$0.06 .

Earnings released on 31 Dec 2023

EPS came in at -$0.13 falling short of the estimated -$0.13 by -2.55%.

Earnings released on 30 Sept 2023

EPS came in at -$0.15 falling short of the estimated -$0.14 by -4.70%.

Earnings released on 30 Jun 2023

EPS came in at -$0.19 falling short of the estimated -$0.16 by -21.55%.

Earnings released on 31 Mar 2023

EPS came in at -$0.84 falling short of the estimated -$0.25 by -236.00%.

Earnings released on 31 Dec 2022

EPS came in at -$0.29 surpassing the estimated -$0.38 by +22.55%.

Earnings released on 30 Sept 2022

EPS came in at -$0.37 .

Earnings released on 30 Jun 2022

EPS came in at -$0.56 falling short of the estimated -$0.43 by -28.34%.

Earnings released on 31 Mar 2022

EPS came in at -$0.50 .

Earnings released on 31 Dec 2021

EPS came in at -$0.40 .

Earnings released on 30 Sept 2021

EPS came in at -$0.62 .

Earnings released on 30 Jun 2021

EPS came in at -$0.37 .

Earnings released on 31 Mar 2021

EPS came in at -$1.60 .

Earnings released on 31 Dec 2020

EPS came in at -$0.44 .

Earnings released on 30 Sept 2020

EPS came in at -$0.19 .

CLYM Stock Performance

Access detailed CLYM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.

Explore Related Stocks

Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.

Discover More
Command Palette
Search for a command to run